SHE: 002755

Company Drug

Aosaikang’s Neratinib Maleate API Market Filing Accepted by NMPA

Fineline Cube Oct 13, 2022

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced that the market filing for its...

Company Drug

Aosaikang’s ASKG315 Receives Ethics Approval for Phase I Cancer Trial in Australia

Fineline Cube Aug 3, 2022

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) announced it has received ethical approval from Australia’s...

Company Drug

Beijing Aosaikang’s ASKG315 Receives NMPA Approval for Solid Tumor Trial

Fineline Cube Jun 16, 2022

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) announced that its clinical trial application for ASKG315,...

Company Drug

Sanofi’s Venglustat Receives FDA Priority Review and Breakthrough Therapy Designation for Type 3 Gaucher Disease

Company Drug

BeOne Medicines and Amgen’s Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China

Company Drug

Northland Biotech’s Engensis Gene Therapy Receives NMPA Approval for Severe Lower Limb Ischemia Ulcers

Company Drug

AstraZeneca’s Fasenra Becomes First Biologic Approved in China for Hypereosinophilic Syndrome